Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atrasentan + carboplatin + docetaxel + gefitinib + gemcitabine + paclitaxel + vinorelbine
- Development stage
- Unknown
- Lead developer
- Abbott
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination of seven different anticancer agents with distinct mechanisms of action. The combination includes: - Atrasentan: An endothelin-A receptor antagonist that inhibits cancer cell proliferation, augments chemotherapy-induced apoptosis, and suppresses angiogenesis - Carboplatin: A platinum-based chemotherapeutic agent that forms DNA adducts and crosslinks, interfering with DNA replication - Docetaxel: A taxane that binds to microtubules, stabilizing them and preventing depolymerization, which leads to cell cycle arrest and apoptosis - Gefitinib: An epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor - Gemcitabine: A nucleoside analog that inhibits DNA synthesis - Paclitaxel: A taxane with a mechanism similar to docetaxel - Vinorelbine: A vinca alkaloid that binds to tubulin and inhibits microtubule assembly
02
Targets
ABCG2 (Breast cancer resistance protein)EDNRA (Endothelin receptor type A)EGFR (Epidermal growth factor receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on atrasentan + carboplatin + docetaxel + gefitinib + gemcitabine + paclitaxel + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atrasentan + carboplatin + docetaxel + gefitinib + gemcitabine + paclitaxel + vinorelbine.